Bill Text: IL SB2213 | 2009-2010 | 96th General Assembly | Introduced
Bill Title: Amends the Illinois Public Aid Code. Makes a technical change in a Section concerning pharmacy payments under the Medicaid program.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2009-08-15 - Pursuant to Senate Rule 3-9(b) / Referred to Assignments [SB2213 Detail]
Download: Illinois-2009-SB2213-Introduced.html
|
||||||||||||||||||||
|
||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
1 | AN ACT concerning public aid.
| |||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois, | |||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||
4 | Section 5. The Illinois Public Aid Code is amended by | |||||||||||||||||||
5 | changing Section 5-5.12 as follows:
| |||||||||||||||||||
6 | (305 ILCS 5/5-5.12) (from Ch. 23, par. 5-5.12)
| |||||||||||||||||||
7 | Sec. 5-5.12. Pharmacy payments.
| |||||||||||||||||||
8 | (a) Every request submitted by a pharmacy for reimbursement | |||||||||||||||||||
9 | under this
Article for prescription drugs provided to a | |||||||||||||||||||
10 | recipient of aid under this
Article shall include the
the name | |||||||||||||||||||
11 | of the prescriber or an acceptable
identification number as | |||||||||||||||||||
12 | established by the Department. | |||||||||||||||||||
13 | (b) Pharmacies providing prescription drugs under
this | |||||||||||||||||||
14 | Article shall be reimbursed at a rate which shall include
a | |||||||||||||||||||
15 | professional dispensing fee as determined by the Illinois
| |||||||||||||||||||
16 | Department, plus the current acquisition cost of the | |||||||||||||||||||
17 | prescription
drug dispensed. The Illinois Department shall | |||||||||||||||||||
18 | update its
information on the acquisition costs of all | |||||||||||||||||||
19 | prescription drugs
no less frequently than every 30 days. | |||||||||||||||||||
20 | However, the Illinois
Department may set the rate of | |||||||||||||||||||
21 | reimbursement for the acquisition
cost, by rule, at a | |||||||||||||||||||
22 | percentage of the current average wholesale
acquisition cost.
| |||||||||||||||||||
23 | (c) (Blank).
|
| |||||||
| |||||||
1 | (d) The Department shall not impose requirements for prior | ||||||
2 | approval
based on a preferred drug list for anti-retroviral, | ||||||
3 | anti-hemophilic factor
concentrates,
or
any atypical | ||||||
4 | antipsychotics, conventional antipsychotics,
or | ||||||
5 | anticonvulsants used for the treatment of serious mental
| ||||||
6 | illnesses
until 30 days after it has conducted a study of the | ||||||
7 | impact of such
requirements on patient care and submitted a | ||||||
8 | report to the Speaker of the
House of Representatives and the | ||||||
9 | President of the Senate.
| ||||||
10 | (Source: P.A. 93-106, eff. 7-8-03; 94-48, eff. 7-1-05.)
|